Back

SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction

31 August 2025 (08:45 - 09:00)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: cardiometabolic medicine Obesity ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Mamas Mamas

Keele University, Keele (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
CONFIDENCE: Results by KDIGO risk category
Doctor M. Vaduganathan (Boston, US)
Slides Video
Presentation thumbnail
SGLT2i and AF
Doctor J. Sedighi (Giessen, DE)
Slides Video
Presentation thumbnail
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
Ms L. Wilson (US)
Slides Video
Presentation thumbnail
STRIDE Outcomes by Sexl
Professor S. Verma (Toronto, CA)
Slides Video
Presentation thumbnail
Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction
Doctor N. Kruger (Boston, US)

Access the full session

Session thumbnail
Late-Breaking Clinical Science: cardiometabolic medicine

The Event

Event poster

ESC Congress 2025

31 August 2025 08:45 CET
You may be interested in
thumbnail
Congress Session
Late-Breaking Clinical Science: cardiometabolic medicine
thumbnail
Congress Presentation
Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources